Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.
Benzinga ·
Benzinga
